Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure

European Journal of Medical Research

Volumn 16, Issue 6, 2011, Pages 275-279

  Hocher, Berthold ^a,b   Heiden, S ^b   Von Websky, K ^a,b   Rahnenfuhrer J ^a,b   Kalk, P ^b,c   Pfab, T ^b,c  

^a UNIVERSITY OF POTSDAM   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute liver failure; D galactosamine; Endothelin; Endothelin converting enzyme; Neutral endopeptidase

Indexed keywords

BIG ENDOTHELIN 1; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; GALACTOSAMINE; LIVER ENZYME; SLV 338; UNCLASSIFIED DRUG; ENDOTHELIN CONVERTING ENZYME; PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; ENZYME BLOOD LEVEL; HEPATITIS; HISTOPATHOLOGY; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MALE; MORTALITY; NONHUMAN; RAT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME INHIBITION; HYPERTRANSAMINASEMIA; LIVER PROTECTION; MINIPUMP; TREATMENT OUTCOME;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; ENDOTHELIN-1; GALACTOSAMINE; LIVER FAILURE, ACUTE; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79960286159     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rosser BG, Gores GJ. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 1995 Jan; 108: 252-75.
2. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology. 1991 Feb; 13: 364-75.
3. Heiden S, Pfab T, von Websky K, Vignon-Zellweger N, Godes M, Relle K, et al. Tissue specific activation of the endothelin system in severe acute liver failure. Eur J Med Res. 2008 Jul 28; 13: 327-9.
4. Anand R, Harry D, Holt S, Milner P, Dashwood M, Goodier D, et al. Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut. 2002 Jan; 50: 111-7. (Pubitemid 34028313)
5. Palmes D, Skawran S, Stratmann U, Armann B, Minin E, Herbst H, Spiegel HU. Amelioration of microcirculatory damage by an endothelin A receptor antagonist in a rat model of reversible acute liver failure. J Hepatol. 2005 Mar; 42: 350-7. (Pubitemid 40254249)
6. Hocher B, Zart R, Diekmann F, Slowinski T, Thone-Reineke C, Lutz J, Bauer C. Protective effects of the mixed endothelin receptor antagonist bosentan in rats with CCL4-induced liver injury. J Cardiovasc Pharmacol. 1995; 26 Suppl 3: S130-S131.
7. Zhang JX, Pegoli W, Jr., Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol. 1994 Apr; 266: G624-G632.
8. Spiegel HU, Scommotau S, Uhlmann D, Giersch B. Effect of the endothelin receptor antagonist bosentan on postischemic liver microcirculation. Zentralbl Chir. 1996; 121: 788-93. (Pubitemid 26355096)
9. Sansoe G, Aragno M, Mastrocola R, Restivo F, Mengozzi G, Smedile A, et al. Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension? J Hepatol. 2005 Nov; 43: 791-8. (Pubitemid 41414504)
10. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994 Aug 12; 78: 473-85.
11. Nagata T, Kudo H, Nishino T, Doi Y, Itoh H, Fujimoto S. Increased immunoreactivities against endothelin-converting enzyme-1 and monocyte chemotactic protein-1 in hepatic stellate cells of rat fibrous liver induced by thioacetamide. Med Mol Morphol. 2005 Sep; 38: 161-72. (Pubitemid 351543873)
12. Shito M, Balis UJ, Tompkins RG, Yarmush ML, Toner M. A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha. Dig Dis Sci. 2001 Aug; 46: 1700-8. (Pubitemid 32727101)
13. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, et al. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol. 2007 Mar; 18: 730-40. (Pubitemid 46434490)
14. Iwai M, Yamauchi T, Shimazu T. Endothelin 1 aggravates acute liver injury in perfused livers of rats after treatment with D-galactosamine. Hepatology. 1998 Aug; 28: 503-9. (Pubitemid 28363679)
15. Uhlmann D, Witzigmann H, Senninger N, Hauss J, Spiegel HU. Protective role of an endothelin-converting enzyme inhibitor (FR901533) in hepatic ischemia/reperfusion injury. Microvasc Res. 2001 Jul; 62: 43-54. (Pubitemid 32679305)
16. Goraca A. New views on the role of endothelin (minireview). Endocr Regul. 2002 Nov; 36: 161-7. (Pubitemid 36534514)